18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

a study on Glaucoma High Blood Pressure Ocular Hypertension

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study start
estimated completion

Description

Summary

Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Official Title

ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice

Keywords

Open-angle Glaucoma, Ocular Hypertension, Bimatoprost intracameral implant (DURYSTA) 10μg

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patient diagnosed with OAG or OHT who is scheduled to receive a bimatoprost intracameral implant in at least one eye.

You CAN'T join if...

  • A history of any of the following ocular surgeries in the eye due to receive a bimatoprost intracameral implant:Ahmed Glaucoma Valve, Baerveldt shunt, Ex-Press glaucoma shunt implantation, Molteno shunt, Trabeculectomy, Vitrectomy, retinal surgery, CyPass Micro-Stent or Anterior Chamber Intraocular Lens (AC IOL) placement.
    • Concurrent or anticipated enrollment in an interventional clinical trial involving either an investigational medicinal product or medical device.
    • Previous enrollment in another Allergan bimatoprost intracameral implant study.

Locations

  • Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240364 accepting new patients
    La Jolla California 92093 United States
  • Angeles Eye Institute /ID# 240368 accepting new patients
    Culver City California 90232 United States
  • American Institute of Research /ID# 247820 accepting new patients
    Los Angeles California 90027 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
ID
NCT04647214
Study Type
Observational
Participants
Expecting 230 study participants
Last Updated
Contact us about this trial